Bristol-Myers Squibb Co. has been given FDA approval of a new label for Sprycel. The new designation recommends a 100-mg starting dose for the product, which treats chronic myeloid leukemia. The company has also announced clearance of Abilify as the first medication for add-on treatment of major depressive disorder.
Related Results
Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation
…
* The FDA has approved Abilify[TM] tablets (aripiprazole), a schizophrenia treatment by Bristol-Myers Squibb and Otsuka Pharmaceuticals. There is no cure for the devastating brain disorder affecting 2.2 million Americans, but it is treatable, and Abilify has demonstrated a favorable side-effect profile in clinical trials.
Related Results
Abilify approvalAbilify approvalNew AbilifyAbilify available as oral solutionNew ABILIFY formulation
Psychiatric drugs …
An oral solution formulation of Abilify (aripiprazole) is now available. Abilify is indicated for the treatment of schizophrenia and for the treatment of acute manic and mixed episodes associated with bipolar disorder. For more information, contact Otsuka America Pharmaceutical Inc., by visiting www.abilify.com,…
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd., have launched ABILIFY[R] DISCMELT[TM] (aripiprazole) Orally Disintegrating Tablets, an oral form of the antipsychotic medication aripiprazole that disintegrates rapidly in the mouth. The FDA approved ABILIFY DISCMELT on June 7. For full prescribing information, including boxed warning, visit www.abilify.com.
Related Results
Abilify approvalAb…
Shared psychotic disorder has also been referred to by other names such as psychosis of association, contagious insanity, infectious insanity, double insanity, and communicated insanity. This disorder usually occurs only in…
Oct. 18, 2005 — A new generation of antipsychotic drugs may slightly increase the risk of death when used to treat common behavioral and psychological problems in people with dementia.
The new drugs include Abilify, Zyprexa, Seroquel, and Risperdal.
A new review of clinical trials that treated people with dementia shows 3.5% of those prescribed the drugs died compared with 2.3% of those who…
BOSTONJuly 15, 2008– Attorney General Martha
Coakley’s Office has entered into an agreement with
international pharmaceutical manufacturer Bristol-Myers Squibb
Company (BMS) to settle a variety of allegations of improper sales,
marketing and price reporting practices. Under the terms of
the settlement, BMS will pay $9,214,659.43 to the Massachusetts
Medicaid Program.
“The Massach…
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c47514) has announced the addition of Bristol-Myers Squibb Prospects to 2010 from Espicom Business Intelligence to their offering.
Headquartered in New York, Bristol-Myer…
First, and the most important is antipsychotic medication. It includes the classic antipsychotic drugs and new generation of antipsychotic medication.
Chlorpromazine, haloperidol and thioridazine are the classic antipsychotic drugs. They have importend side effects, such as: heart palpitations, akathisia, constipation, dry mouth, urinary retention, sexual problems, dizzin…
